We had the pleasure of speaking with Hugh Evans, a member of the board of directors of Collplant Biotechnologies (US: CLGN), about the company’s technology, market opportunity, and business prospects.
A disclosure by Roumell Asset Management piqued our interest in Collplant. According to a fact sheet of Roumell Opportunistic Value Fund, Collplant was the fund’s largest holding as of June 30, comprising 8.0% of net assets.
In light of Roumell’s strong investment track record and our respect for Jim’s long term-oriented, value-based investment approach, we sought to develop an understanding of Collplant by speaking with director Hugh Evans, a former SVP at 3D Systems and a former portfolio manager at T. Rowe Price.
This conversation is available as an episode of Discover Great Ideas, a member podcast of MOI Global. (Learn how to access member podcasts.)
Listen to the conversation (recorded on July 19, 2021):
About the interviewee:
Hugh Evans joined the board of directors of CollPlant in March 2021, bringing his extensive board, 3D printing technology and investment experience. Since 2019, Mr. Evans has been serving as a board member at Factory Four. In addition, since 2020, he has been serving as a board member at ZVerse, 3DM, and as a Non-Executive Chairman of Culinary Printworks. From 2010 to 2020, Mr. Evans served as a board member of AquaVenture Holdings (NYSE: WAAS), which was acquired by Culligan International.In 2019, Mr. Evans founded Additive Manufacturing Ventures Group, and he serves as a managing member. From 2013 to 2019, Mr. Evans served as Senior Vice President of Corporate Development & Digitization at 3D Systems (NYSE: DDD). Previously, from 1992 to 2013, he served as a portfolio manager at T. Rowe Price Associates (NASDAQ: TROW). Mr. Evans holds a BA in Psychology from the University of Virginia and an MBA from the Stanford Graduate School of Business.The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.